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clinical outcomes in cancer patients. At decreased oxygen tensions, hypoxia-inducible factors (HIFs) 1 and 2
are stabilized andmediate a hypoxic response, primarily by acting as transcription factors. HIFs exert differential
effects on tumor growth and affect important cancer hallmarks including cell proliferation, apoptosis, differenti-
ation, vascularization/angiogenesis, genetic instability, tumor metabolism, tumor immune responses, and inva-
sion and metastasis. As a consequence, HIFs mediate resistance to chemo- and radiotherapy and are associated
with poor prognosis in cancer patients. Intriguingly, perivascular tumor cells can also express HIF-2α, thereby
forming a “pseudohypoxic” phenotype that further contributes to tumor aggressiveness. Therefore, therapeutic
targeting of HIFs in cancer has the potential to improve treatment efﬁcacy. Different strategies to target hypoxic
cancer cells and/or HIFs include hypoxia-activated prodrugs and inhibition of HIF dimerization, mRNA or protein
expression, DNA binding capacity, and transcriptional activity. Here we review the functions of HIFs in the
progression and treatment of malignant solid tumors. We also highlight how HIFs may be targeted to improve
the management of patients with therapy-resistant and metastatic cancer.
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. This is an open access article under1. Introduction
An adequate oxygen supply to cells and tissues is crucial for the func-
tion and survival of aerobic organisms. Hypoxia occurs when oxygen
supply fails tomeet demand. The deﬁnition of hypoxia is somewhat am-
biguous since normal oxygen pressure (PO2) varies between different
tissues. For instance, the normal PO2 in arterial blood is ~100 mm Hg
(~13%) but ~40 mm Hg (~5%) in the liver (Koh & Powis, 2012). No
clear-cut threshold separates normoxia from hypoxia, so oxygen levels
must be regarded in context. Likewise, deﬁnitions of mild, moderate,
and severe hypoxia are not clearly deﬁned. Nevertheless, 8–10 mm Hgthe CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
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associated with adverse effects caused by reduced O2 consumption
(Hockel & Vaupel, 2001). For in vitro studies, 1% oxygen is commonly
used to mimic a hypoxic environment. Solid malignant tumors
commonly contain hypoxic areas, and direct measurement of tissue
oxygenation using O2-sensitive microsensors has shown that the
tumor microenvironment is characterized by much lower PO2 values
than their normal counterparts (Vaupel et al., 2004).
A major cause of tumor hypoxia is the formation of non-functional
blood vessels in neoplastic tissue, particularly in rapidly growing
tumors. Hypoxia is not merely epiphenomenal but is of clinical impor-
tance since tumor hypoxia is associated with aggressive tumor pheno-
types, treatment resistance, and poor clinical prognosis (reviewed in
Bertout et al. (2008)). The cellular response to hypoxia is mainly medi-
ated by the hypoxia-inducible factor (HIF) family of transcription fac-
tors, which regulate the expression of multiple genes involved in
processes that drive the adaptation and progression of cancer cells.
Therefore, tumor hypoxia andHIFs affectmost of the cancer “hallmarks”
including cell proliferation, apoptosis, metabolism, immune responses,
genomic instability, vascularization, and invasion and metastasis. HIFs
also appear to contribute to chemo- and radiotherapy resistance viaFig. 1. Hallmarks of cancer regulated by hypoxia and HIFs. Hypoxia and HIFs regulate multi
progression, metastasis, and treatment resistance. Abbreviations: VEGF, vascular endothelial g
oxidative phosphorylation; SSB, single-strand break; TAM, tumor-associated macrophage; CTL
DC, dendritic cell; MDR, multi-drug resistance; ROS, reactive oxygen species; IR, ionizing radiamultiple mechanisms. In clinical tumor samples, HIF expression is asso-
ciated with poor prognoses and relapse on treatment. HIFs appear to be
crucial molecular targets that can be exploited to improve on the cur-
rent treatment of metastatic and treatment-resistant cancer.
However, HIF biology is complex. Alternative HIF isoforms differential-
ly regulate tumor growth; consequently, optimalHIF targeting depends on
the speciﬁc tumor type andHIF-1 andHIF-2 selectivity. Strategies to inhib-
it HIFs in cancer include drugswith indirect effects onHIF signaling, but di-
rect HIF inhibitors also exist. In this reviewwe describe HIF regulation and
function, their role as master regulators of solid tumor hallmarks (Fig. 1),
the pseudohypoxic phenotype, and the different therapeutic strategies
that have been developed to inhibit HIF activity (Fig. 2).
2. Regulation and function of hypoxia-inducible factors
HIFs are proteins that sense and respond to oxygen deﬁciency by
acting as transcription factors (Fig. 2). Each HIF transcription factor is
composed of two subunits: the α-subunit and the β-subunit, both of
which belong to the basic helix–loop-helix (HLH)-PER-ARNT-SIM
(bHLH-PAS) protein family (Bersten et al., 2013). The α-subunit is oxy-
gen sensitive, while the β-subunit (HIF-1β or ARNT) is ubiquitouslyple cancer phenotypes. Targeting hypoxia/HIFs will thus inhibit several traits of tumor
rowth factor; PDGF-β, platelet-derived growth factor-β; ANGPT2, angiopoietin 2; oxphos,
, cytotoxic T-lymphocyte; Treg, regulatory T-cell; MDSC, myeloid-derived suppressor cell;
tion.
Fig. 2. Regulation of HIF-α under normoxic and hypoxic conditions. Under normoxic conditions, HIF-α undergoes hydroxylation at conserved residues, a process mediated by prolyl-4-
hydroxylases (PHDs) and factor inhibiting HIF-1 (FIH-1) enzymes. Hydroxylation by PHDs promotes destabilization of the HIF-α protein, while hydroxylation by FIH-1 inhibits
transcriptional activity by preventing interaction with CBP/p300. Degradation of HIF-α is mediated via an ubiquitin-dependent process executed by the VHL-complex. Inactivation of
PHDs and FIH-1 under hypoxic conditions leads to HIF-α stabilization followed by translocation into the nucleus and dimerization with HIF-1β/ARNT to form the HIF transcription
factor. Together with the co-activator CBP/p300, HIFs induce transcription of a plethora of target genes during hypoxia. The small molecules that can modulate HIF activity at different
levels are also shown.
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the α-subunit are hydroxylated, promoting its degradation (Ivan
et al., 2001; Jaakkola et al., 2001). This hydroxylation is mediated by
prolyl-4-hydroxylases (PHDs), a set of oxygen-, iron-, and ascorbate-
dependent enzymes belonging to the 2-oxoglutarate-dependent oxy-
genase superfamily (Schoﬁeld &Ratcliffe, 2004). Theα-subunit hydrox-
ylation serves as a recognition signal for the von Hippel–Lindau (pVHL)
tumor suppressor protein, which subsequently targets the α-subunit
for degradation by adding ubiquitin. However, under hypoxic condi-
tions, PHDs cannot hydroxylate theα-subunit. This results inHIF-αpro-
tein stabilization, nuclear translocation, and dimerization with HIF-1β
to form the HIF transcription factor. In the nucleus, HIFs bind to the
A/GCGTG consensus motif in target gene promoter regions, known
as hypoxia-responsive elements (HREs). By recruiting transcriptional
co-activators, HIFs regulate the expression of numerous genes involved
in different processes including angiogenesis, metabolism, erythropoie-
sis, apoptosis, pH regulation, metastasis, and cellular differentiation
(Semenza, 2003; Keith et al., 2012).
There are three different α-subunit isoforms: HIF-1α, HIF-2α,
and HIF-3α. HIF-1α and HIF-2α have been most comprehensively
studied, with less known about HIF-3α. Semenza and colleagues
ﬁrst described HIF-1α in the nineties (Wang et al., 1995), while
Tian et al. (1997) described the second isoform (initially called
EPAS1; endothelial PAS protein 1) soon after, ﬁndings that were
quickly conﬁrmed by several other groups. The α-subunits show
conserved sequence homology (Fig. 3), mostly in the bHLH- andPAS-A and PAS-B domain-containing N-terminal region that mediates
DNA binding and interactionwith HIF-1β. Two transactivation domains
(TADs) located in the α-subunit N- and C-termini regulate HIF tran-
scriptional activity: the N-TAD is located in the region where hydroxyl-
ation takes place, known as the oxygen-dependent degradation (ODD)
domain. HIF transcriptional activity is also regulated by a second
oxygen-sensitive hydroxylation event mediated by factor inhibiting
HIF-1 (FIH-1) (Mahon et al., 2001; Lando et al., 2002). FIH-1 is a 2-
oxoglutarate-dependent oxygenase (similar to the PHDs), and it cata-
lyzes hydroxylation of an asparagine residue in the C-TAD of HIF-α,
thereby preventing interaction with the p300/CBP co-activator. Of
note, HIF-1α is more sensitive to FIH-1-mediated inhibition than HIF-
2α (Khan et al., 2011) due to a speciﬁc amino acid difference between
the two HIFs (Bracken et al., 2006). The afﬁnity of PHDs and FIH-1 for
oxygen differs and, since FIH-1 has a higher afﬁnity (lower Km) for
oxygen, PHDs are thought to be more rapidly inhibited in low oxygen
conditions (Pouyssegur et al., 2006). Thus, when PHDs are inactive,
the HIF-1α subunit is stabilized but FIH-1 can still inhibit transcription
of genes that require HIF-1α C-TAD activity. Depending on the oxygen
tension, different gene sets might be regulated according to their N-
TAD or C-TAD requirement. Hypoxia-associated factor (HAF) is an E3
ubiquitin ligase that switches cells from HIF-1- to HIF-2-dependent sig-
naling by targeting HIF-1α for degradation and increasing HIF-2α
transactivation (Koh et al., 2011).
The fact that there is less sequence homology in the HIF-1α
and HIF-2α transactivating domains than the DNA-binding and
Fig. 3. Domain structures of HIF-α isoforms. The HIF-α subunits contain a basic HLH (helix–loop–helix) domain for DNA-speciﬁc binding and two sequential PAS (PER-ARNT-SIM)
domains (PAS-A and PAS-B) that facilitate heterodimerization with HIF-1β/ARNT. There are two transcription-activation domains (TADs), one N-terminal domain (N-TAD), and one C-
terminal domain (C-TAD). The N-TAD is located in the oxygen-dependent degradation (ODD) domain. Conserved residues where PHDs and FIH-1 hydroxylate HIF-α are speciﬁed.
Abbreviation: NLS, nuclear localization signal.
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target genes. Early studies showed that HIF-1 (but not HIF-2) induced
expression of several glycolytic genes in various cell types,while unique
HIF-2 target genes seemed to be cell type speciﬁc (Hu et al., 2003; Raval
et al., 2005). The studies were mainly performed in VHL-defective renal
cell carcinoma (RCC) cell lines with unique HIF expression patterns,
i.e., expressing only HIF-2α or both HIF-1α and HIF-2α. HIF transcrip-
tional target speciﬁcity was strikingly different in VHL-defective RCC
cells compared to other cell types, and the HIF isoforms also showed a
mutually dependent suppressive function in RCC (Raval et al., 2005).
Several investigators have used chromatin immunoprecipitation to-
gether with microarrays (ChIP-chip) to directly identify HIF target
genes (Mole et al., 2009; Xia & Kung, 2009; Xia et al., 2009). These stud-
ies conﬁrmed the core A/GCGTG HIF-binding motif and, in agreement
with earlier ﬁndings, showed that HIF-1 targets genes important in gly-
colyticmetabolism. Furthermore, genes encoding histone demethylases
were identiﬁed asHIF-1 target genes, suggesting that HIFs participate in
epigenetic homeostasis during hypoxia. These studies also identiﬁed
considerable overlap between HIF-1 and HIF-2 binding sites, yet HIF-2
seemed to contribute very little to the transcriptional changes during
hypoxia (Mole et al., 2009). Integrating data from ChIP-chip analyses
with gene expression proﬁles over a hypoxia time course showed that
HIF-1 stabilization causes HIF-1 to preferentially bind to loci already
transcriptionally active prior to the onset of hypoxia, partially
explaining why most hypoxia-induced transcriptional changes are cell
type speciﬁc (Xia & Kung, 2009). A study using chromatin immunopre-
cipitation followed by next-generation high-throughput sequencing
(ChIP-seq) showed that HIF binding sites exist outside of promoter se-
quences and that HIF binds to other sites as well as the core A/GCGTG
motif (Schodel et al., 2011). This was particularly true for HIF-2α, for
which as many as 70% of the identiﬁed HIF-2 binding sites lay outside
promoter regions. Consistent with other studies, glucose metabolism
pathways were targeted by HIF-1, while HIF-2 targeted genes were in-
volved in Oct4-regulated stem cell pluripotency. A representative list of
shared and unique target genes regulated by HIF-1 and HIF-2 can be
found in Keith et al. (2012). Moreover, while HIF-1 is thought to medi-
ate the acute response to hypoxia, HIF-2 stabilizes over longer time
frames and also at normal physiological oxygen levels (Holmquist-
Mengelbier et al., 2006).
In addition to its role as a transcription factor subunit, HIF-2α is also
part of a hypoxia-regulated translation initiation complex. Hypoxia in-
duces the formation of a HIF-2α complexwith the RNA-binding proteinRBM4 and cap-binding protein eIF4E2, which is then recruited to awide
variety of mRNAs to promote active translation at polysomes (Uniacke
et al., 2012). This function is independent of HIF-1β dimerization.
As well as direct gene targeting via HRE binding, both HIF-1α and
HIF-2α can indirectly inﬂuence gene expression by interfering with
the activity of other transcription factors such as MYC (Koshiji et al.,
2004; Gordan et al., 2007a), p53 (Chen et al., 2003; Bertout et al.,
2009), and Notch (Gustafsson et al., 2005; Hu et al., 2014). Importantly,
for many of these interactions, HIF-1α and HIF-2α seem to have
completely opposing effects, a difference that needs to be considered
when targeting HIFs for therapeutic beneﬁt. Further adding to HIF com-
plexity, α-subunits are differentially regulated at the transcriptional,
translational, and posttranslational modiﬁcation levels. A comprehen-
sive description of HIF-α regulation and the conﬂicting roles of HIF-1α
and HIF-2α are given in Keith et al. (2012).
Although a major mode of HIF stabilization is via proline hydroxyl-
ation and VHL-mediated degradation, it is important tomention that sev-
eral non-hypoxia-driven stimuli also regulate HIFs such as growth factors,
cytokines, hormones, and various stressors. Several growth factors and
their cognate receptors that signal through the phosphoinositide 3-
kinase (PI3K) or Ras/MAPK pathways induce HIF expression, and both
basal and mitogen-induced HIF expression is abrogated upon PI3K path-
way inhibition (Zhong et al., 2000; Beppu et al., 2005; Calvani et al.,
2008;Mohlin et al., 2015). HIFs are direct substrates of a variety of protein
kinases that regulate HIF stabilization, nuclear translocation, and activa-
tion (Kietzmann et al., 2016). Interestingly, several factors also use
reactive oxygen species (ROS) as intermediate signaling molecules, and
it has been shown that ROS directly regulate HIFs at different levels
(Gorlach & Kietzmann, 2007).
3. Hypoxia and hypoxia-inducible factors in cancer
3.1. Measuring tumor hypoxia
In early key ﬁndings, O2-sensitive microsensors were used to show
that tumor hypoxia was associated with tumor progression (Vaupel &
Mayer, 2007). Patients with hypoxic head and neck tumors (Gatenby
et al., 1988; Nordsmark et al., 2005), cervical cancer (Hockel et al.,
1993; Hockel et al., 1996), and soft tissue sarcoma (Nordsmark et al.,
2001) had a worse prognosis, although some results are conﬂicting
(Nordsmark et al., 2006). Endogenous biomarkers associated with hyp-
oxia in vitro (e.g., HIF-1α, glucose transporters, and carbonic anhydrase
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surprisingly, low O2 measured by microsensors did not correlate with
expression of these biomarkers in patient tumors (Mayer et al.,
2008a). Thus, even if endogenous “hypoxic” biomarkers are associated
with poor clinical prognosis (as described below), it is worth remem-
bering that a direct association between biomarker expression and
intratumoral hypoxia is unproven, and tumor cells can also express
“hypoxia” markers such as HIF-2α under normoxic conditions
(discussed below and reviewed in Pietras et al. (2010)). Different
methods for measuring hypoxia in patients are reviewed in Vaupel
et al. (2004).
3.2. Patient prognosis
TheHIF-1α protein is overexpressed in various common solidmalig-
nant tumors including breast, colon, gastric, lung, skin, ovarian, pancre-
atic, prostate, and renal carcinomas compared to their respective
normal tissues. In contrast, many benign tumors show very little or
no HIF-1α expression (Zhong et al., 1999; Daponte et al., 2008;
Simiantonaki et al., 2008; Mayer et al., 2008b). Importantly, HIF-1α or
HIF-2α overexpression is associated with poor clinical outcomes in pa-
tients with various cancers. HIF-1α expression is associated with poor
survival in cervical cancer (Birner et al., 2000), endometrial carcinoma
(Sivridis et al., 2002), oligodendroglioma (Birner et al., 2001a), ovarian
cancer (Birner et al., 2001b), and different breast cancer subtypes (Bos
et al., 2001; Schindl et al., 2002; Bos et al., 2003; Generali et al., 2006;
Kronblad et al., 2006). The prognostic value of HIF-1α in breast cancer
has, however, been questioned in conﬂicting follow-up studies,
but HIF-2α appears to be an independent prognostic factor in breast
cancer (Helczynska et al., 2008). HIF-2α expression is also a marker of
poor prognosis in glioblastoma (Li et al., 2009), neuroblastoma
(Holmquist-Mengelbier et al., 2006), head and neck squamous carcino-
ma (Koukourakis et al., 2002), and non-small cell lung cancer
(Giatromanolaki et al., 2001). In ccRCC, VHL loss impairs degradation
of HIF-α proteins, leading to HIF accumulation irrespective of oxygen
levels (Gnarra et al., 1994; Krieg et al., 2000). The pathways involved
in the pseudo-hypoxic phenotype in ccRCC are further reviewed in
Bratslavsky et al. (2007). High nuclear expression of HIF-1α and high
cytoplasmic expression of HIF-2α indicate poor prognosis in ccRCC pa-
tients (Fan et al., 2015). Thus, while intratumoral hypoxia in general is
associated with poor prognosis, the prognostic role of HIF-1α and HIF-
2α differs between tumor types. In addition, HIF-1α overexpression is
associatedwith improved prognosis in patients with head and neck can-
cer (Beasley et al., 2002), non-small cell lung cancer (Volm & Koomagi,
2000), and favorable outcomes in neuroblastoma (Noguera et al., 2009).
Thus, similar to their molecular functions, HIF-1α and HIF-2α can have
opposite clinical effects depending on the tumor type.
3.3. Tumor cell viability
Hypoxia can result in decreased cell proliferation, cell cycle arrest,
and/or apoptosis. Giaccia and co-workers demonstrated that hypoxia
can induce tumor cell apoptosis, an effect that was reduced by loss of
p53 tumor suppressor function or overexpression of anti-apoptotic
Bcl-2 (Graeber et al., 1996). Therefore, hypoxia can exert a selective
pressure that leads to expansion of tumor cells with reduced apoptotic
capacity due to, for example, TP53 mutations (Graeber et al., 1996). It
has been suggested that hypoxia induces a physical interaction between
HIF-1α and p53, resulting in stabilization of p53 and increased apopto-
sis (An et al., 1998). The interaction betweenHIF-1α and p53 is, howev-
er, also mediated by Mdm2, and HIF-1α can increase p53 levels by
inhibition of Mdm2-mediated degradation (Chen et al., 2003). Intrigu-
ingly, p53 can also promote Mdm2-mediated degradation of HIF-1α
(Ravi et al., 2000). HIF-2α seems to have an opposing effect on p53 (at
least in ccRCC) since HIF-2α inhibits p53 in an Mdm2-independent
manner, thereby providing therapeutic opportunities via HIF-2αinhibition (Bertout et al., 2009; Roberts et al., 2009). The interplay be-
tween HIFs and the p53 family is reviewed in Amelio and Melino
(2015).
c-Myc is an essential cell cycle regulator and oncogene, and HIFs can
either interfere with or promote c-Myc activity. Hypoxia-induced HIF-
1α inhibits c-Myc transcription and suppresses proliferation (Koshiji
et al., 2004), and HIF-1α can also promote c-Myc degradation (Zhang
et al., 2007). In contrast, HIF-2α can enhance c-Myc activity and pro-
mote cell cycle progression (Gordan et al., 2007a). HIF-1α can further
inhibit Myc by interfering with its partner protein Myc-associated pro-
tein X (Max), while HIF-2α can stabilize theMyc–Max complex and in-
crease Myc activity. The complex interplay between HIFs and Myc is
reviewed in Dang et al. (2008). These opposing effects on Myc function
further highlight the need to develop speciﬁc inhibitors that target ei-
ther HIF-1α or HIF-2α. The effects of hypoxia and HIFs on tumor cell
proliferation, survival, and apoptosis are reviewed in Gordan et al.
(2007b) and Keith et al. (2012).
In response to stressors such as hypoxia or nutrient deprivation, cells
become dependent on increased autophagy for their survival. In
autophagy – literally “eating of self” – autophagosomes are formed
that sequester intracellular components prior to digestion by fusion
with lysosomes. Basal levels of autophagy are needed for cellular ho-
meostasis, but from the cancer perspective, autophagy is considered a
double-edged sword since it can either be tumor suppressive or tumor
promoting. Its suppressor effects arise because it prevents cells from
being damaged by unfolded proteins or damaged organelles. However,
it can also promote tumor growth by providing tumor cells withmetab-
olites and by preventing the accumulation of malfunctioningmitochon-
dria that would otherwise lead to increased ROS and cell death. HIF-1 is
directly involved in regulating mitochondrial autophagy by inducing
expression of the BH3-only proteins BNIP3 andBNIP3L,whichpromotes
release of Beclin-1, a major autophagy regulator (Zhang et al., 2008a;
Bellot et al., 2009). For a more detailed review on autophagy in cancer
we refer interested readers to White (2012).
3.4. Tumor angiogenesis
A key feature of the hypoxic response is the upregulation of multiple
genes that promote angiogenesis/vascularization to increase oxygende-
livery. Cells grown under hypoxic conditions activate transcription of
vascular endothelial growth factor (VEGF) (Shweiki et al., 1992;
Forsythe et al., 1996), which is important for endothelial cell activation
and proliferation. Other hypoxia-induced pro-angiogenic factors in-
clude platelet-derived growth factor-β (PDGF-β) (Kelly et al., 2003),
angiopoietin-2 (ANGPT2) (Kelly et al., 2003), and stromal-derived
factor 1α (SDF-1α) (Ceradini et al., 2004), all of which promote
neoangiogenesis. In neuroblastoma, HIF-1 mediates acute hypoxia-
induced VEGF expression, while HIF-2 regulates VEGF expression
during prolonged hypoxia (Holmquist-Mengelbier et al., 2006).
Furthermore, HIF-1α loss decreases tumor vascularization and impairs
vascular function (Carmeliet et al., 1998), and HIF-2α knockdown in
glioblastoma and neuroblastoma results in poorly vascularized tumors
(Li et al., 2009; Pietras et al., 2009). Vascularization is severely impaired
in HIF1A−/− (Carmeliet et al., 1998; Ryan et al., 1998) and HIF2A−/−
(Peng et al., 2000) mice. Thus, both HIF-1 and HIF-2 play crucial roles
in tumor vascularization, although their effect may vary depending on
the temporal and cellular context.
3.5. Cancer stem cells
Hypoxia and HIFs regulate the proliferation and differentiation of
different stem cell populations including embryonic, neural, and hema-
topoietic stem cells. The stem cell-like state ismediated by upregulation
of OCT4, Notch, c-Myc, and telomerase (Keith & Simon, 2007). Certain
tumor cells are known to possess cancer stem cell (CSC)-like features,
although the presence of true CSCs in solid tumors remains to be
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exist as a distinct sub-population of the cancer cell population, it is
clear that hypoxia and HIFs regulate stem cell-like features in a propor-
tion of cancer cells and make them more aggressive. In neuroblastoma,
hypoxia downregulates neuronal and neuroendocrine differentiation
markers and upregulates genes expressed during normal neural crest
development (Jogi et al., 2002). HIF-2α is co-expressed with putative
CSC markers in neuroblastoma and glioblastoma (Pietras et al., 2008;
Li et al., 2009). Furthermore, HIF-2α silencing in glioblastoma decreases
self-renewal, tumor cell proliferation in vitro, and tumor-initiating ca-
pacity in vivo (Li et al., 2009). We and others have hypothesized that
HIF inhibition promotes tumor cell differentiation and reduces tumor
relapse after conventional therapy (Keith & Simon, 2007; Lofstedt
et al., 2007).
3.6. Metabolic reprogramming
Reprogramming of energy metabolism is another hallmark of can-
cer. In 1924, Otto Warburg observed that cancer cells metabolize glu-
cose differently than untransformed cells. Instead of metabolizing
glucose via the tricarboxylic acid (TCA) cycle and producing maximum
amounts of ATP via oxidative phosphorylation, cancer cells redirect glu-
cose metabolism away from these circuits. Instead of converting pyru-
vate generated from glycolysis into acetyl-CoA (for the TCA cycle),
cancer cells convert pyruvate into lactate, the latter reaction only gener-
ating twoATPmolecules per glucosemolecule compared to 36ATPmol-
ecules per glucose molecule during normal TCA cycling and oxidative
phosphorylation. Under oxygen deprived conditions, untransformed
cells also convert pyruvate into lactate, a process known as “anaerobic
glycolysis”. However, cancer cells convert pyruvate into lactate even
when oxygen is available, so their metabolism is often referred to as
“aerobic glycolysis”, or “the Warburg effect” (Vander Heiden et al.,
2009). Warburg proposed that cancer cells use aerobic glycolysis due
to impaired mitochondrial function; however, later studies have
shown that most cancer cells have functional mitochondria. Further-
more, studies on proliferating primary lymphocytes have shown that
glucose is primarily converted to lactate, demonstrating that aerobic
glycolysis is not only restricted to cancer cells (DeBerardinis et al.,
2008). This raises the question: whywould proliferating cells, including
cancer cells, choose a pathway that produces less ATP? Even though this
question has not been fully answered, one explanation could be that
proliferating cells do not need optimized metabolism for maximal ATP
production because the nutrient supply is not limited, so aerobic glycol-
ysis still produces sufﬁcient ATP. Another reason might be that cells re-
quire other molecules in addition to ATP to divide. Macromolecules
such as amino acids, nucleotides, and fatty acids are needed for cellular
replication and, consequently, pathways that support synthesis of these
biomolecules are preferentially selected (DeBerardinis et al., 2008;
Vander Heiden et al., 2009). Lactate is a byproduct of aerobic glycolysis
and is considered amajor player in tumor acidiﬁcation. However, recent
studies suggest that lactate also plays a role as a signalingmolecule and
can modulate the tumor microenvironment, providing a rationale to
target lactic acid transporter complexes. Further reading on the
therapeutic beneﬁt of targeting lactate transporters can be found in
Marchiq and Pouyssegur (2016)).
Hypoxia promotes aerobic glycolysis by increasing both glucose up-
take and expression of glycolytic enzymes (Iyer et al., 1998). Further-
more, Kim et al. provided the ﬁrst evidence that HIF-1 actively
participates inmetabolic reprogramming from the TCA cycle to glycoly-
sis by showing that HIF-1 directly targets the gene encoding pyruvate
dehydrogenase kinase 1 (PDK1) (Kim et al., 2006). PDK1 inactivates py-
ruvate dehydrogenase (PDH), which catalyzes pyruvate into actetyl-
CoA; therefore, by regulating PDK1 expression, HIF-1 steers cells toward
glycolysis and away from the TCA cycle. This knowledge has led to the
testing of drugs that inhibit glycolysis such as dichloroacetic acid
(DCA), which inhibits PDK activity (Dunbar et al., 2014).Although hypoxia and HIF signaling are important for glycolysis,
other mechanisms regulate glycolytic metabolism. For instance, the on-
cogenic PI3K signaling pathway also promotes glucose uptake and me-
tabolism. HIFs regulate a switch from glucose to glutamine metabolism
to produce acetyl-CoA in fatty acid synthesis (Semenza, 2013). Cancer
cells often consume glutamine, and those dependent on Myc signaling
are highly sensitive to glutamine withdrawal (Yuneva et al., 2007).
Furthermore, tumor suppressor pathways such as p53 and LKB1/
AMPK signaling also regulate cellular metabolism (Vander Heiden
et al., 2009). For further information on the role of hypoxia in metabolic
reprogramming we refer readers to Masson and Ratcliffe (2014) and
Semenza (2013).3.7. Tumor immune response
Inﬂammation is another cancer hallmark, and the anti-tumor im-
mune response plays a crucial role in many cancer types (Hanahan &
Weinberg, 2011). Intratumoral hypoxiamodulates the tumoral immune
response in many ways, collectively pointing to an overall immunosup-
pressive effect (Palazon et al., 2012). For instance, tumor hypoxia and/or
HIFs can attract myeloid-derived suppressor cells (Corzo et al., 2010),
regulatory T-cells (Clambey et al., 2012), and tumor-associated macro-
phages (Doedens et al., 2010; Imtiyaz et al., 2010) with immunosup-
pressive functions. Hypoxia can also suppress dendritic cell function
and inhibit inﬁltrating cytotoxic T-lymphocyte activity in a HIF-1α-
dependent manner (Barsoum et al., 2014; Palazon et al., 2012). Adeno-
sine accumulates in tumors during hypoxic stress and contributes to
tumor progression via immune suppression and a direct effect on cancer
cells. Adenosine is thus a crucial factor mediating the hypoxic inhibition
of the anti-tumor immune response (Antonioli et al., 2013). In addition,
hypoxia-induced HIF-1α drives expression of the immune checkpoint
protein PD-L1, which contributes to immune suppression and evasion
(Noman et al., 2014). Therefore, most evidence suggests that HIFs
exert a tumor-promoting effect by immunosuppression. Immunothera-
py has recently shown great promise in cancer patients, especially for
the treatment of metastatic melanoma, and the combination of HIF
inhibitors and immunotherapy may be a useful approach for clinical
testing to further improve outcomes.3.8. Genomic instability
Intratumoral hypoxia promotes genomic instability, another hall-
mark ofmost cancers (Bristow&Hill, 2008). Early studies demonstrated
that cancer cells cultured under hypoxic conditions contain an increased
number of mutations and exhibit diminished DNA repair following
UV irradiation-induced DNA damage compared to normoxic cells
(Reynolds et al., 1996; Yuan et al., 2000). Furthermore, hypoxia
downregulates DNA repair gene expression, and hypoxia/reoxygena-
tion cycles can induce DNA strand breaks and oxidative base damage,
gene ampliﬁcations, and DNA over-replication (Bristow & Hill, 2008).
Hypoxia can also lead to the epigenetic regulation and silencing of
the DNA repair gene BRCA1, thereby promoting genomic instability
(Lu et al., 2011). HIF-1α is responsible for genetic instability in cancer
cells by inhibiting the DNA mismatch repair genes MSH2 and MSH6,
which leads to decreased levels of the MSH2-MSH6 (MutSα) base mis-
match recognition complex (Koshiji et al., 2005). Hypoxia-induced HIF-
1 upregulates microRNAs miR-201 and miR-373, thereby suppressing
DNA repair pathways and causing additional genetic instability
(Crosby et al., 2009). Conversely, HIF-2 does not have the same effects
on genomic stability, in part due to Thr-324 phosphorylation in the
PAS-B domain, which prevents HIF-2 from repressing DNA repair
genes (To et al., 2006). Furthermore, HIF-2 regulates the expression
of genes involved in protecting cells from DNA damaging ROS
(Scortegagna et al., 2003).
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Metastasis is the main cause of cancer-related deaths. Intratumoral
hypoxia is associated with metastasis in experimental tumors (Young
et al., 1988; Brizel et al., 1996; Cairns et al., 2001; De Jaeger et al.,
2001), and HIFs have been implicated in metastatic disease in various
clinical studies (Zhong et al., 1998; Zhong et al., 1999; Dales et al.,
2005; Holmquist-Mengelbier et al., 2006; Helczynska et al., 2008).
Interestingly, HIF-1α was overexpressed in 29% of primary breast
cancers but 69% of breast cancer metastases (Zhong et al., 1999). In-
sights from a transgenic mouse model of metastatic breast cancer
(Liao et al., 2007) and xenograft models of breast cancer (Hiraga
et al., 2007; Lu et al., 2010) also point to HIF-1α as a critical regulator
of metastasis.
Mechanistically, hypoxia and HIFs are involved in many different
steps of the metastatic process. Epithelial-to-mesenchymal transition
(EMT) is an initial step inwhich tumor cells lose expression of the inter-
cellular adhesion molecule E-cadherin (encoded by CDH1) and acquire
a motile phenotype. Hypoxia and HIFs contribute to EMT by upregulat-
ing transcriptional repressors such as SNAIL (Imai et al., 2003), TWIST
(Yang et al., 2008), TCF3, ZFHX1A, and ZFHX1B (Krishnamachary et al.,
2006), whose gene products in turn repress CDH1. Loss of VHL in
ccRCC also downregulates E-cadherin in a HIF-dependent manner
(Esteban et al., 2006).
Hypoxia and HIFs can also induce tumor cell invasion and degrada-
tion of the extracellular matrix via various mechanisms including upreg-
ulation of cathepsin D, urokinase-type plasminogen activator receptor,
and matrix metalloproteinases-1 and -2 (Krishnamachary et al., 2003;
Munoz-Najar et al., 2006) and activation of Met (Pennacchietti et al.,
2003). The RIOK3 kinase promotes re-organization of the actin cytoskel-
eton in a HIF-1α-dependent manner, which has been shown to increase
breast cancer cell migration and invasion/metastasis (Singleton et al.,
2015). HIF-1 activates transcription of collagen prolyl hydroxylases,
which promote collagen deposition and breast cancer cell migration
along collagen ﬁbers, thereby enhancing invasion and metastasis
(Gilkes et al., 2013). HIF regulates lysyl oxidase, a critical mediator of
hypoxia-induced breast cancer cell migration and metastasis, which
mediates its action through increased focal adhesion kinase activity
and extracellular matrix modulation (Erler et al., 2006).
Hypoxia-induced VEGF production promotes lymph- and angiogen-
esis,which facilitate tumor cell intravasation and dissemination (Claffey
et al., 1996; Schoppmann et al., 2006). VEGF can also contribute to sys-
temic intravasation by increasing microvascular permeability (Claffey
et al., 1996; Dvorak et al., 1999). HIF-1α-dependent expression of
angiopoietin-like 4 and the L1 cell adhesion molecule further modulate
intra- and extravasation (Zhang et al., 2012).
Tumor cell homing to distant sites involves the HIF-regulated che-
mokine receptor CXCR4 (Staller et al., 2003), which binds to stromal-
derived factor-1 (SDF-1α) in secondary organs and drives breast cancer
metastasis (Muller et al., 2001). Primary tumor hypoxia can also pro-
motemetastatic spread by establishing a pre-metastatic niche in distant
organs. Speciﬁcally, hypoxia-induced lysyl oxidase contributes to the
pre-metastatic niche in a process that includes collagen crosslinking
and recruitment of CD11b+ myeloid cells (Erler et al., 2009). Finally,
HIF expression in tumor stromal cells can also affect metastasis: HIF-2
expression in tumor endothelial cells has been shown to increase
tumor cell migration and metastasis, while endothelial HIF-1 reduces
cell migration and metastasis (Branco-Price et al., 2012).
We refer readers to Rundqvist and Johnson (2010) for a detailed
review of HIFs in breast cancer metastasis and to Johnson et al. (2015)
for a review of the role of hypoxia and HIFs in bone metastasis.
3.10. Treatment resistance
Intrinsic resistance and acquired resistance to radiotherapy (ionizing
radiation; IR) and chemotherapy aremajor reasons for treatment failurein cancer patients. It has been known since the 1950s that hypoxia is a
crucial mediator of chemo- and radioresistance (Gray et al., 1953;
Roizin-Towle & Hall, 1978). HIF overexpression in clinical samples is as-
sociated with therapeutic resistance or decreased survival following IR
or chemotherapy (Aebersold et al., 2001; Birner et al., 2001b;
Koukourakis et al., 2002; Burri et al., 2003; Generali et al., 2006; Vergis
et al., 2008).
Under normoxic conditions, IR generates ROS that cause irreparable
DNA damage and cell death. Intratumoral hypoxia prevents ROS forma-
tion, resulting in inefﬁcient DNA strand breaks and IR resistance (Brown
& Wilson, 2004). HIF-1α expression is temporarily and acutely de-
creased after IR due to re-oxygenation of surviving hypoxic tumor
cells (Harada et al., 2009). ROS production later stabilizes the HIF-1α
protein and increases expression of HIF-1α and its target genes
(Moeller et al., 2004; Dewhirst et al., 2008; Harada et al., 2009). HIF-
1α appears to exert both radiosensitizing (e.g., by promoting prolifera-
tion and p53-induced apoptosis) and radioresistant effects (via vascular
radioprotection) (Moeller et al., 2005). HIF-1α-mediated alterations in
tumor glucose metabolism may also affect cellular responses to IR
(Meijer et al., 2012). Importantly, silencing or pharmacological inhibi-
tion of HIF-1α can increase the anti-tumor effects of IR (Zhang et al.,
2004; Moeller et al., 2005; Harada et al., 2009; Harada et al., 2012).
HIF-2α contributes to tumor cell survival after IR, and HIF-2α inhibition
can increase the IR effect by activating the p53 pathway and increasing
apoptosis (Bertout et al., 2009). Thus, HIF inhibitors can be used in com-
bination with radiotherapy to target radiotherapy-resistant tumor cells.
Furthermore, radiosensitizers such as misonidazole mimic the effect of
oxygen and can be used to enhance IR efﬁciency in hypoxic tumors,
particularly in head and neck cancers (Brown & Wilson, 2004).
A number of studies suggest that HIFs mediate chemoresistance.
One main mechanism by which HIF-1 mediates chemoresistance is by
activating the multidrug resistance 1 (MDR1) gene (Comerford et al.,
2002), which encodes a glycoprotein belonging to the ATP-binding cas-
sette (ABC) transporter family and functions as a drug efﬂux pump. In
thisway, HIF-1α andMDR1 can decrease the intracellular concentration
of various chemotherapeutic drugs and contribute to hypoxia-induced
drug resistance (Comerford et al., 2002). Similarly, HIF-2 can activate
transcription of another ABC transporter ABCG2, suggesting a potential
mechanism of HIF2-induced chemoresistance (Martin et al., 2008).
Hypoxia and/or HIFs canmediate chemotherapy resistance through ad-
ditional mechanisms including: a) hypoxia-induced decreases in tumor
cell proliferation (Tannock, 1968); b) metabolic reprogramming;
c) hypoxia-driven selection of p53-mutated tumor cells with less apo-
ptotic capacity (Graeber et al., 1996); and d) inhibition of DNA damage
(Sullivan & Graham, 2009). Taken together, these data on the role of
HIFs in therapeutic resistance suggest that HIF1/2 inhibitors might be
effective in combination with conventional chemotherapy (Unruh
et al., 2003; Erler et al., 2004; Brown et al., 2006; Nardinocchi et al.,
2009; Roberts et al., 2009; He et al., 2012; Zhao et al., 2014). For a com-
prehensive review of the mechanisms underlying HIF-induced chemo-
therapeutic resistance, we refer the reader to Rohwer and Cramer
(2011).4. Targeting hypoxia and hypoxia-inducible factors in cancer
Since hypoxia is a hallmark of solid tumors andmediates aggressive,
metastatic, and resistant disease, it is arguably one of themost attractive
therapeutic targets in cancer. Several approaches for targeting hypoxic
tumor cells have been proposed including hypoxia-activated prodrugs,
gene therapy, recombinant anaerobic bacteria, speciﬁc targeting of
HIFs, or targeting pathways important in hypoxic cells such as
the mTOR and UPR pathways (Melillo, 2007; Wilson & Hay, 2011;
Semenza, 2012). We brieﬂy discuss the mechanism of action of
hypoxia-activated prodrugs before describing in detail the drugs that
directly or indirectly modulate HIFs (see Fig. 2 and Table 1).
Table 1
Inhibitors of HIF activity by different mechanisms and targets.
Inhibitory mechanism Drug Target References
mRNA/protein expression Wortmannin PI3K Jiang et al., 2001
LY94002 PI3K Jiang et al., 2001; Mohlin et al., 2015
GDC-0941 PI3K Mohlin et al., 2015
PI-103 PI3K Mohlin et al., 2015
Rapamycin mTOR Hudson et al., 2002
PP242 mTOR Mohlin et al., 2015
Aminoﬂavone unknown Terzuoli et al., 2010
Glyceollins AKT/mTOR, Hsp90 Lee et al., 2015
Topotecan, PEG-SN38 Topoisomerase 1 Rapisarda et al., 2004, Pastorino et al., 2010
EZN-2968 HIF-1αmRNA Greenberger et al., 2008
2ME2, ENMD-1198 Microtubules Mabjeesh et al., 2003; LaVallee et al., 2008
Geldanamycin and analogs Hsp90 Isaacs et al., 2002
Vorinostat HDAC Hutt et al., 2014
YC-1 unknown Chun et al., 2001, Li et al., 2008
PX-478 unknown Koh et al., 2008
PX-12, pleurotin Thioredoxin-1 Welsh et al., 2003
Cardiac glycosides unknown Zhang et al., 2008b
FM19G11 unknown Moreno-Manzano et al., 2010
HIF-2α translational inhibitors IRP1/IRE interaction Zimmer et al., 2008
HIF-α/HIF-1β dimerization Acriﬂavine HIF-1α/2α PAS-B domain Lee et al., 2009
PT2385 HIF-2α PAS-B domain Scheuermann et al., 2013
DNA binding Echinomycin HRE Kong et al., 2005
Polyamides HRE Olenyuk et al., 2004
Transcriptional activity Chetomin p300 recruitment Kung et al., 2004
Bortezomib p300 recruitment Kaluz et al., 2006, Shin et al., 2008
Amphotericin B FIH-1 interaction and p300 recruitment Yeo et al., 2006
Triptolide Hsp70 Zhou et al., 2010
AJM290, AW464 Thioredoxin-1 Jones et al., 2006
PI3K, phosphoinositide 3-kinase; mTOR, mechanistic/mammalian target of rapamycin; Hsp90, heat shock protein 90; HDAC, histone deacetylase; IRP1, iron-responsive element-binding
protein 1; IRE, iron response element; HRE, hypoxia response element; FIH-1, factor inhibiting HIF-1; Hsp70, heat shock protein 70.
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A prodrug is an inactive compound that can, either spontaneously or
via speciﬁc metabolic pathways, be converted to its pharmacologically
active species. One way of exploiting tumor hypoxia has been to design
hypoxic prodrugs that are activated in hypoxic tissue and thus selective-
ly kill hypoxic tumor cells (Denny, 2000). Hypoxic prodrugs are activat-
ed by reduction of the prodrug by cellular reductases. One-electron
reductases generate a prodrug radical that is either re-oxidized to the
initial prodrug in oxic cells or is converted into its cytotoxic species in
hypoxic cells (Fig. 4). Alternatively, two-electron reductases bypass
the prodrug radical formation step and directly convert the prodrug
into the active drug. Since no oxygen-sensitive prodrug radical is
formed in the two-electron reduction pathway, this reaction is typically
(but not always) oxygen insensitive andmore likely to lead to off-target
effects. The cytotoxic effect of the active metabolite is mainly mediated
by DNA interactions and by interfering with replication. Furthermore,
surrounding non-hypoxic tumor cells can be killed through the so-
called “bystander” effect, which can be enhanced by prolonging the
half-life of the cytotoxic metabolite. Examples of hypoxia-activated
prodrugs are provided in Table 2. For further reading on hypoxic
prodrugs, we refer the reader to Phillips (2016).Fig. 4. Activation mechanism of hypoxic prodrugs. The prodrug can be converted into its acti
produces a prodrug radical that can be further reduced into the active toxic compound in hy
prodrugs are reduced by two-electron reductases, thus bypassing the formation of a prodrug rThe hypoxic prodrug tirapazamine has been extensively tested in
clinical trials, but results have been disappointing (Rischin et al., 2010;
DiSilvestro et al., 2014). A second-generation tirapazamine analog
SN30000 has improved pharmocodynamic and pharmacokinetic prop-
erties and superior anti-tumor effects in xenograft models (Hicks
et al., 2010). Some of the disappointment in clinical trials may have
been due to a failure to adopt a “personalized” or precision approach:
to optimize the potential therapeutic effect, it is crucial that patients
are stratiﬁed based on tumor-speciﬁc predictive biomarker expression
that indicates sensitivity to the drug being tested. However, predictive
biomarkers for hypoxic prodrugs are poorly deﬁned. Interestingly,
P450 oxidoreductase was recently identiﬁed as a biomarker of sensitiv-
ity to the hypoxia prodrugs SN30000 and TH-302 (Hunter et al., 2015).
Results from recently published phase II clinical trials for TH-302 in
combination with gemcitabine in pancreatic cancer (Borad et al.,
2015) or in combination with doxorubicin in soft tissue sarcoma
(Chawla et al., 2014) are encouraging, and phase III studies have been
initiated. The prodrug apaziquone (EO9), a mitomycin C derivative,
showed efﬁcacy in preclinical studies, but clinical trials were negative.
An evaluation of why apaziquone failed showed that the drug had
poor pharmacokinetics: the drug could not penetrate the tumor and
was rapidly degraded on systemic delivery (Phillips et al., 2013).ve compound either by one-electron or two-electron reduction. One-electron reduction
poxic cells or be re-oxidized back to the prodrug in normoxic cells. Alternatively, some
adical.
Table 2
Examples of hypoxia prodrugs in preclinical and clinical trials.
Prodrug Clinical trial status Cancer NCT
TH-302 (Evofosfamide) Phase III Soft tissue sarcoma NCT01440088
Phase III (active) Pancreatic cancer NCT01746979
EO9 (Apaziquone) Phase III
(completed)
Bladder cancer NCT00598806
NCT00461591
Phase III (active) NCT01410565
NCT02563561
NCT01469221
AQ4N Phase I/II Multiple NCT00394628
Phase I/II NCT00109356
Phase I NCT00090727
PR-104 Phase I/II
(completed)
Acute leukemia NCT01037556
Tirapazamine (TPZ) Phase III
(completed)
Cervical cancer NCT00262821
Head and neck
cancer
NCT00174837
NCT00094081
Lung cancer NCT00017459
NCT00006484
SN30000 (CEN-209) Preclinical
TH-4000 Phase II (active) Non small cell
lung cancer
NCT02454842
Squamous cell
carcinoma
NCT02449681
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a superior option to avoid problems with drug delivery and clearance.
Loco-regional administration of apaziquone in superﬁcial bladder can-
cer, an excellent model due to the capacity for direct prodrug delivery
to the cancer via a catheter, has shown efﬁcacy. A phase III trial of
apaziquone (EOquin®) as adjuvant therapy in patients with bladder
cancer treated by surgery was recently completed (NCT00598806).
4.2. Drugs targeting hypoxic signaling
Strategies to target hypoxia include direct and indirect HIF targeting
as well as targeting of downstream HIF signaling pathways. A classic
example of the latter is anti-VEGF-therapy: monoclonal antibodies
targeting VEGF (bevacizumab) or small molecule inhibitors targeting
the VEGF receptor have shown clinical beneﬁt in advanced cancer
(Ellis & Hicklin, 2008). There are considerably fewer selective and
speciﬁc HIF inhibitors compared to non-selective inhibitors that target
multiple pathways including the HIF pathway. Nonetheless, the non-
selective inhibition of HIFs might be an important anti-tumor mecha-
nism in practice. In the following section (and Fig. 2), we summarize
the drugs that have been shown to directly or indirectly target HIFs or
their pathways.
4.2.1. Inhibitors of hypoxia-inducible factor
messenger ribonucleic acid or protein expression
Aminoﬂavone is an aryl hydrocarbon receptor ligand, has been
shown to partially inhibit HIF-1α mRNA expression in breast cancer
cells and almost completely inhibit HIF-1α protein accumulation and
transcription of downstream target genes in an aryl hydrocarbon
receptor-independent fashion (Terzuoli et al., 2010). However, its clini-
cal utility has not been demonstrated, and several clinical trials using
the prodrug AFP-464 have either been terminated or withdrawn prior
to enrollment due to lack of efﬁcacy.
Inhibitors of phosphoinositide 3-kinase/mechanistic/mammalian target of
rapamycin. Apart from the well-deﬁned oxygen-mediated regulation
of HIF-α subunits, translation of HIF-αmRNA is controlled by growth
factor signaling pathways such as the PI3K/AKT/mTOR pathway. Thus,
molecules that target this pathway presumably also modulate HIFactivity. Consistent with this, several studies have shown thatmTOR in-
hibition decreases HIF-1α and HIF-2α levels under both normoxic and
hypoxic conditions (Hudson et al., 2002; Majumder et al., 2004;
Thomas et al., 2006; Mohlin et al., 2015). We recently showed that
hypoxia-inducedHIF2A transcription in neuroblastoma cells is highly de-
pendent on PI3K-mTORC2 but not PI3K-mTORC1, further supporting the
hypothesis that targeting this pathway abrogates HIF activity (Mohlin
et al., 2015). A novel group of HIF-1 inhibitors called glyceollins (isolated
from soybeans) can also block HIF-1α translation by inhibiting the PI3K/
AKT/mTOR pathway under hypoxic conditions (Lee et al., 2015).
Topoisomerase 1 inhibitors. Irinotecan and topotecan are FDA-approved
topoisomerase I inhibitors and analogs of the naturally occurring cyto-
toxic alkaloid camptothecin. Topotecan was identiﬁed as an inhibitor
of HIF-1 activity (Rapisarda et al., 2002) and was later shown to inhibit
HIF-1α translation (Rapisarda et al., 2004). More recently, the
camptothecin-induced effects on HIF-1α levels were shown to occur
as a result of changes in miRNA expression (Bertozzi et al., 2014). In a
small pilot trial, topotecan decreased HIF-1α protein expression in 4
out of 7 paired tumor biopsies taken from patients before and after
treatment (Kummar et al., 2011). In an ongoing phase II study of
bevacizumab and irinotecan in young patients with brain tumors, one
of the secondary outcomes is measurement of HIF-2α expression at
baseline and association of HIF-2α expression with progression-free
survival. SN-38 is the active metabolite of irinotecan, and attachment
of polyethylene glycol (PEG) to SN-38 improves drug solubility: PEG-
SN38 (or EZN-2208) has been shown to downregulate both HIF-1α
and HIF-2α in a neuroblastoma model (Pastorino et al., 2010), and a
phase I study of PEG-SN38 in patients with neuroblastoma and other
solid tumors showed low toxicity and supported further study of this
drug in neuroblastoma (Norris et al., 2014). Furthermore, PEG-SN38 in
combination with all-trans retinoic acid was synergistic in a mouse
model of acute promyelocytic leukemia (Coltella et al., 2015).
Synthetic oligonucleotides. EZN-2968 is a synthetic antisense oligonu-
cleotide comprised of 16 nucleotide residues 100% complementary to
residues in the mRNA coding sequence of human HIF-1α. EZN-2968
binding leads to HIF-1α mRNA downregulation in a dose-dependent
manner and results in near complete inhibition at 5 nM concentrations
(Greenberger et al., 2008). EZN-2968 has a three base pair mismatch
with the HIF-2α sequence and, as a consequence, only downregulates
HIF-2α mRNA by 20% at 25 nM. EZN-2968 treatment of tumor cells
in vitro downregulated HIF-1α protein levels during hypoxia and re-
duced the growth rate. The in vivo effect of EZN-2968 has also been test-
ed in a subcutaneous prostate cancer cell line xenograft model and,
although treatment did not result in a signiﬁcant reduction in tumor
burden, pre-treatment of cells with EZN-2968 prior to injection resulted
in a signiﬁcant reduction in tumor size. EZN-2968 has also been evaluat-
ed in two phase I clinical trials: results from one trial showed reduced
HIF-1αmRNA in post-treatment biopsies from 4 out of 6 patients with
paired tumor biopsies, and HIF-1α protein and mRNA levels of target
genes were reduced in biopsies from two patients. Although the trial
provided preliminary proof of concept for modulation of HIF-1α
mRNA and protein expression in response to EZN-2968, the trial closed
prematurely due to suspended development of the compound (Jeong
et al., 2014). A third phase I trial has recently been initiated in patients
with hepatocellular carcinoma to establish proof-of-mechanism for
EZN-2968 (RO7070179).
2-Methoxyestradiol (2ME2) and analogs. 2ME2 is a microtubule-
targeting estrogen metabolite that causes mitotic arrest. 2ME2 inhibits
tumor growth and angiogenesis by downregulating HIF-1α protein ex-
pression, most likely through translational inhibition (Mabjeesh et al.,
2003). A recent report has suggested that 2ME2 also downregulates
HIF-2α to overcome sorafenib resistance in hepatocellular carcinoma
cells (Ma et al., 2014). The safety and efﬁcacy of 2ME2 (Panzem™)
161C. Wigerup et al. / Pharmacology & Therapeutics 164 (2016) 152–169have been evaluated in numerous phase I and phase II studies, and there
have been efforts to generate more effective 2ME2 analogs. To this end,
ENMD-1198 has been selected as a lead analog (LaVallee et al., 2008)
and has been tested in a phase I dose-escalation study in advanced can-
cer patients (Zhou et al., 2011).
Heat shock protein inhibitors. Heat shock proteins (Hsp) are cellular
chaperones that ensure that target proteins are correctly folded and lo-
calized. Geldanamycin (GA) is an anti-cancer antibiotic that promotes
protein degradation by binding and inhibiting Hsp90. GA can induce
proteasomal degradation of HIF-1α in a VHL-independent manner
both under normoxic and hypoxic conditions (Isaacs et al., 2002). The
GA analogs 17-AAG (tanespimycin) and 17-DMAG (alvespimycin)
have been evaluated in several phase I and phase II trials either alone
or in combination with other chemotherapies. In a comparative analy-
sis, a next-generation smallmoleculeHsp90 inhibitor EC154more effec-
tively inhibited HIF-1α and HIF-2α than 17-AAG (Bohonowych et al.,
2011). This study highlights the discordance between HIF activity and
HIF protein expression, emphasizing that pharmaceutical inhibition of
HIF activity is not necessarily equivalent to HIF tissue expression and,
therefore, HIF biomarker analysis is not always a robust surrogate of
HIF suppression.
Triptolide, isolated from a Chinese herb, mediates its anti-tumor ef-
fects by inhibiting Hsp70. Somewhat unexpectedly, triptolide increased
HIF-1α levels under both normoxic and hypoxic conditions, although
target gene transcriptionwas reduced suggesting that triptolide inhibits
HIF-1 activity (Zhou et al., 2010). The triptolide prodrug Minnelid™ is
currently being tested in a phase I trial of patientswith advanced gastro-
intestinal tumors (NCT01927965).
Histone deacetylase (HDAC) inhibitors. HDACs remove acetyl groups
from histones or non-histone proteins such as transcription factors.
The HDAC inhibitors vorinostat (SAHA, Zolinza®), romidepsin
(Istodax®, previously known as FK228), panobinostat (Farydak®), and
belinostat (Beleodaq®, also known as PXD101) are FDA approved for
the treatment of various cancers. HDAC inhibitors have been shown to
promote HIF-1α degradation and, although the exact mechanism is
not completely understood, translational inhibition of HIF-1α has
been proposed as vorinostat's mechanism of action (Hutt et al., 2014).
Another mechanism of HDAC inhibitor action might be via Hsp90 inhi-
bition, as described above. Both HIF-1α and HIF-2α are themselves reg-
ulated by acetylation and deacetylation events but in opposingmanners
(Keith et al., 2012). Deacetylation of HIF-2α by SIRT1, a deacetylase, in-
creases HIF-2α's transcriptional activity, while deacetylation of HIF-1α
results in transcriptional repression. This suggests that HDAC inhibitors
can have direct but contrasting effects on HIF-α subunits.
YC-1 was originally discovered as an activator of soluble guanylate
cyclase, an enzyme that increases cGMP levels and, as a result, inhibits
platelet aggregation and vasoconstriction. Additionally, YC-1 has anti-
tumor effects by inhibiting HIF activity via an unknown non-guanylate
cyclase-mediated mechanism. Treatment of hepatocellular carcinoma
Hep3B cells with YC-1 decreased hypoxic induction of erythropoietin
(EPO) and VEGF, decreased HIF-1α protein accumulation, and reduced
HIF-1/DNA binding (Chun et al., 2001). Bearing in mind that EPO is a
speciﬁc HIF-2 target (Rankin et al., 2007), the observed downregulation
of EPO in Hep3b cells by YC-1 suggests that YC-1 also inhibits HIF-2 ac-
tivity. YC-1 is thought to inhibit HIF-1 activity by preventing its interac-
tion with the p300 co-activator (Li et al., 2008), i.e., the same
mechanism used by the endogenous FIH enzyme. However, empirically
thismechanismwas cell line dependent andwas not observed in Hep3b
cells. This suggests that EPO downregulation in Hep3b cells upon YC-1
treatment is not mediated by preventing HIF interaction with p300
but rather via another unknown mechanism. This is consistent with
the observation that HIF-2 is not regulated to the same extent as HIF-1by FIH. YC-1 also has anti-tumor and anti-angiogenic effects in several
xenograft models (Yeo et al., 2003) and has also been shown to inhibit
tumor cell invasion and metastasis (Shin et al., 2007), but there have
been no YC-1 clinical trials to date. Based on YC-1's structure, new ana-
logs have been synthesized and screened for their HIF inhibitory effects
(Masoud et al., 2015).
PX-478 is derived from the alkylating agent melphalan, a cytotoxic
agent used in the treatment of multiple myeloma and some other can-
cers including ovarian cancer. PX-478 inhibits HIF-1α atmultiple levels,
primarily by translational inhibition and, to a lesser extent, by promot-
ing protein degradation in an oxygen-, pVHL-, and p53-independent
manner (Koh et al., 2008). PX-478 has shown anti-tumor activity in
several xenograft models (Welsh et al., 2004), and a phase 1 dose-
escalation study of PX-478 in patients with advanced solid tumors or
lymphoma showed, at best, stable disease in 14 out of 36 evaluable pa-
tients (Ban et al., 2011).Thioredoxin inhibitors. PX-12 is an inhibitor of the redox protein
thioredoxin (Trx-1). Trx-1 is found at high levels in many human can-
cers and is also associated with increased expression of HIF-1α and
HIF-regulated genes (Welsh et al., 2002). Two Trx-1 inhibitors, PX-12
and pleurotin, were initially found to decrease HIF-1α and VEGF levels
in vitro and in vivo (Welsh et al., 2003). However, a phase II trial of
PX-12 in patients with advanced pancreatic cancer was terminated
early due to lack of signiﬁcant efﬁcacy (Ramanathan et al., 2011). Two
novel Trx-1 inhibitors, AJM290 andAW464, also inhibitedHIF transcrip-
tional activity and DNA binding but, unexpectedly and in contrast to
other Trx-1 inhibitors, stabilized both HIF-1α and HIF-2α (Jones et al.,
2006).
Cardiac glycosides were identiﬁed as HIF inhibitors in a cell-based
screen (Zhang et al., 2008b). Both HIF-1α and HIF-2α protein expres-
sion were reduced during treatment with the cardiac glycosides oua-
bain, proscillaridin A, and digoxin. In contrast, HIF-1α mRNA levels
increased during treatment. Of note, the in vitro doses used were
much higher than circulating therapeutic doses of digoxin and would,
therefore, be expected to induce severe toxicity (Lopez-Lazaro, 2009).
Also, species-related differences in cardiac glycoside sensitivity might
contribute to the anti-tumor effects of digoxin observed in mice
harboring humanmalignant cells. A phase II breast cancer trial recently
commenced in which changes in HIF-1α protein expression in
tumor tissue will be evaluated in patients taking daily digoxin for
two weeks prior to surgery compared to no drug prior to surgery
(NCT01763931).
FM19G11was identiﬁed as a novel, low cytotoxicity inhibitor of HIF
transcriptional activity in a cell-based screen (Moreno-Manzano et al.,
2010). Both HIF-1α and HIF-2α protein accumulation was inhibited
during hypoxia independent of proteasome activity, and FM19G11
also promoted differentiation of hypoxic neural stem cells, possibly
through downregulation of Sox2 and Oct4.Hypoxia-inducible factor-2α translational inhibitors.HIF-2α translation is
regulated by an iron-dependent mechanism involving an iron-
responsive element (IRE) in the 5′-UTR of the HIF-2αmRNA (Sanchez
et al., 2007). The IREs can bind iron-regulatory proteins (IRPs), which
then repress mRNA translation. Binding of IRP1 to the IRE in the 5′-
UTR of HIF-2α mRNA is impaired during hypoxia, leading to de-
repression of HIF-2α mRNA translation. However, when intracellular
iron levels are low, IRP1 still binds to the IRE and represses HIF-2α
mRNA translation. Zimmer et al. identiﬁed compounds that could re-
press HIF-2α activity by promoting IRP1 binding to the IRE in the HIF-
2α 5′-UTR (Zimmer et al., 2008).
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The PAS domains in the HIF-α and HIF-1β/ARNT subunits mediate
HIF complex assembly, and small molecules that target these domains
have been screened to discover inhibitors of this protein–protein
interaction.
Acriﬂavine is a potent inhibitor of HIF-α-HIF-1β dimerization by
directly binding to the PAS-B domain of both HIF-1α and HIF-2α (Lee
et al., 2009). Treatment with acriﬂavine reduced tumor growth and
vascularization in prostate and hepatocellular xenograft models
(Lee et al., 2009).
PT2385. Based on the crystal structures of the PAS-HIF-2α and PAS-HIF-
1β heterodimers, the HIF-2α PAS-B domainwas found to harbor a large
internal cavity (Scheuermann et al., 2009). Interestingly, an allosteric li-
gand that binds in this cavity and inhibits HIF-2 transcriptional activity
has recently been described (Scheuermann et al., 2013). The ligand did
not affect HIF-2αmRNAand protein levels; thus, this inhibitor is unlike-
ly to affect HIF-1β-independent HIF-2α mechanisms such as transla-
tional activation. Based on this ligand, a novel compound PT2385 has
now entered a phase 1 dose-escalation trial in patients with advanced
ccRCC (NCT02293980). Since HIF-2α rather than HIF-1α is the major
driver of VHL-mutated ccRCC (Kondo et al., 2003; Carroll & Ashcroft,
2006), speciﬁc targeting of HIF-2 in this tumor is likely to be more
beneﬁcial.
4.2.3. Inhibitors of hypoxia-inducible factor-deoxyribonucleic acid binding
Transcriptional activation of target genes by HIFs requires DNA
binding. Inhibiting this step is another potential mechanism to inhibit
HIF activity.
Echinomycin is a small antibiotic molecule isolated from Streptomy-
ces echinatus that binds DNA in a sequence-speciﬁc manner. In cell-
based screening, echinomycin inhibited binding of HIF-1 to HREs and
thus prevented induction of hypoxia-induced VEGF expression (Kong
et al., 2005). In a mouse model of relapsed acute myeloid leukemia,
echinomycin cured mice without affecting normal hematopoietic stem
cells (Wang et al., 2014). Nevertheless, clinical trials of echinomycin
have been disappointing, and thus its therapeutic relevance remains
to be established (Melillo, 2007).
Polyamides. Synthetic oligomers containing N-methylpyrrole and N-
methylimidazole amino acids can bemodiﬁed to target speciﬁc DNA se-
quences to modulate gene expression. A polyamide designed to target
HREs inhibited binding of HIF-1 to the VEGFHRE and blockedVEGF syn-
thesis (Olenyuk et al., 2004). A recent study compared polyamide up-
take in different tumor xenografts and showed that there was
signiﬁcant variability in compound uptake in xenografts of different or-
igin (Raskatov et al., 2014). Polyamides are currently not in clinical use.
4.2.4. Inhibitors of hypoxia-inducible factor transcriptional activity
N-TAD and C-TAD, the two functional HIF domains, are responsible
for mediating their transcriptional activity by interacting with co-
activators such as p300/CBP. Therefore, transcriptional inhibition has
been pursued as a therapeutic strategy by interfering with this HIF-
p300 interaction.
Chetomin, a Chaetomium fungus metabolite, was identiﬁed as a po-
tent disrupter of the HIF-p300 interaction in a high-throughput screen-
ing study of N600,000 substances (Kung et al., 2004). Chetomin
inhibited binding of both HIF-1α and HIF-2α to p300 and in vivo anti-
tumor effects were also demonstrated. In a later study, chetomin wasshown to disrupt zinc-binding sites in the p300 CH1domain,which hin-
dered the HIF-p300 interaction (Cook et al., 2009). Gliotoxin and
chaetocin are other naturally occurring metabolites belonging to the
same family as chetomin, and they have also been shown to block the
HIF-p300 interaction (Reece et al., 2014). However, due to chetomin's
toxicity, this drug has not been pursued clinically (Onnis et al., 2009).
Proteasome inhibitors. Bortezomib (Velcade™) is an FDA-approved pro-
teasome inhibitor for the treatment of multiple myeloma and mantle
cell lymphoma. Bortezomib blocked hypoxia-induced CAIX, EPO, and
VEGF accumulation in cell lines by inhibiting HIF-1α C-TAD's transcrip-
tional activity (Kaluz et al., 2006; Shin et al., 2008). However, data were
conﬂicting as to whether this was due to repression of the HIF-1-p300
interaction. Since bortezomib blocked hypoxic EPO production in
Hep3B cells (Shin et al., 2008), HIF-2 activity was also presumably com-
promised, but this was not investigated. As a single agent in a phase II
trial, bortezomibwas inactive in patientswithmetastatic colorectal can-
cer even though tumor biopsies collected pre- and post-treatment
showed HIF-1α accumulation and reduced CAIX levels, indicating that
hypoxic signaling pathways were affected (Mackay et al., 2005).
Falchook et al. hypothesized that bortezomib combined with
bevacizumab would overcome anti-angiogenic therapy resistance by
blocking HIF-1α upregulation, although the published study only re-
cruited a small number of patients and a lack of paired biopsies preclud-
ed any robust analysis of changes in HIF-1α and downstream targets
(Falchook et al., 2014).
Amphotericin B (AmB) is used to treat systemic fungal infections, but
long-term treatment is associatedwith anemia, supposedly by EPO sup-
pression. Yeo et al. showed that AmB treatment downregulated EPO
mRNA and protein levels in rat kidneys and Hep3B cells (Yeo et al.,
2006). Only HIF-1α protein levels were investigated in this study, and
AmB affected neither protein levels nor HIF-1α localization, suggesting
that reduced EPO was due to repressed HIF-1α C-TAD activity via en-
hanced interaction between HIF-1α and FIH-1. However, the downreg-
ulation of EPO implies that AmB could also inhibit HIF-2 activity.
5. Neural crest-derived tumors as model systems for targeting
hypoxia-inducible factor-2 and the pseudohypoxic phenotype
The neural crest-derived sympathoadrenal stem cell gives rise to a
sympathetic nervous system (SNS) composed of cells from three differ-
entiation lineages, namely the ganglionic/neuronal, chromafﬁn, and SIF
(small intensely ﬂuorescent) lineages (Landis & Patterson, 1981). Sever-
al observations suggest that HIF-2 signaling has speciﬁc roles during
SNS development. HIF-2α is transiently and speciﬁcally expressed in
human embryonal and fetal SNS cells and during rodent SNS develop-
ment (Tian et al., 1998; Nilsson et al., 2005; Mohlin et al., 2013). Fur-
thermore, hypoxia and HIFs are important regulators of the synthesis
(Schnell et al., 2003) and secretion (Kumar et al., 1998) of catechol-
amines, which are key SNS neurotransmitters. Consistent with these
observations, mouse embryos lacking HIF-2α have severely reduced
norepinephrine levels compared to wild type mice (Tian et al., 1998).
Human tumors develop from at least the ganglionic and the chro-
mafﬁn SNS lineages. Pheochromocytomas and paragangliomas arise
from chromafﬁn cells in the adrenal medulla and extra-adrenal sympa-
thetic paraganglia, respectively, and affect adults and, rarely, children.
Neuroblastomas arise from sympathetic neural precursor cells in the
adrenal medulla or sympathetic ganglia and are bona ﬁde childhood tu-
mors. The vast majority of pheochromocytomas and paragangliomas
are benign, in contrast to neuroblastomas that present with metastases
at the time of diagnosis in about a half of patients. Interestingly, the tu-
morigenesis of these closely related tumors seems to involve aberrant
HIF-2 signaling, resulting in pseudohypoxic phenotypes linked to dis-
seminated disease (Eisenhofer et al., 2004; Pietras et al., 2008; Favier
et al., 2009). Somatic gain-of-function mutations in HIF2A have been
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2012; Comino-Mendez et al., 2013; Lorenzo et al., 2013; Taieb et al.,
2013; Toledo et al., 2013; Yang et al., 2013), while high HIF-2α expres-
sion is associated with poor survival in patients with neuroblastoma
(Holmquist-Mengelbier et al., 2006). Interestingly, HIF-2α-positive
neuroblastoma cells have been identiﬁed in perivascular niches
(Holmquist-Mengelbier et al., 2006; Pietras et al., 2008), indicating
that HIF-2α protein is stabilized in these cells despite sufﬁcient oxygen
and facilitating the pseudohypoxic phenotype in tumor cells. Thus,
these SNS-derived tumors provide models to study HIF-2's role in tu-
morigenesis and metastasis and to test novel treatment protocols that
target HIF-2 directly or indirectly by interfering with upstream or
downstream pathways (Richter et al., 2013; Mohlin et al., 2015).
Pheochromocytomas and paragangliomas have the largest heredi-
tary component of all human tumors, and many of the associated
germlinemutations (such as those in VHL and succinate dehydrogenase
(SDH)) result in pseudohypoxic phenotypes (Dahia, 2014). As noted
above, VHL is a crucial mediator of HIF-α degradation at normoxia;
thus, VHL loss stabilizes HIF-α and results in pseudohypoxia. Mutations
in SDHx (SDHA, SDHB, SDHC or SDHD) lead to succinate accumulation,
which acts as a competitive inhibitor of the 2-oxoglutarate-dependent
dioxygenases such as the PHDs, again stabilizing HIF-α and causing
pseudohypoxia.
Unsupervised hierarchical classiﬁcation of gene expression proﬁles
of pheochromocytomas and paragangliomas distinguishes two main
clusters. Cluster 1 includes HIF2A-, VHL-, and SDHx-related tumors
and is characterized by expression of genes involved in hypoxic signal-
ing and high expression of HIF-2α itself (Eisenhofer et al., 2004;
Lopez-Jimenez et al., 2010). Tumors with SDHBmutations seem to be
more aggressive and metastatic (Amar et al., 2007; King et al., 2011),
and although the molecular explanation for this phenomenon has not
been fully established, a potential role for active HIF-2 signaling has
been proposed (Guzy et al., 2008). HIF-2α, therefore, appears to be a
highly relevant target in most, if not all, cluster 1 pheochromocytomas
and paragangliomas.Moreover, HIF-2α silencing in PC-12 rat pheochro-
mocytoma cells led to increased expression of the catecholamine-
synthesizing enzyme PNMT, while HIF-1α silencing had the opposite
effect (Qin et al., 2014), again suggesting opposing roles for these two
HIFs in SNS-derived tumor cells.
Clinically relevant in vitro and in vivo models are required to effec-
tively evaluate drugs that target HIF-2 in neural crest-derived tumors.
A number of xenograft models and genetically engineered mouse
models (GEMMs) have been developed for neuroblastoma and pheo-
chromocytoma (Table 3 and further reviewed in Korpershoek et al.Table 3
Animal models of neuroblastoma and pheochromocytoma/paraganglioma.
Model Tumor Metastasis Reference(s)
Xenografts
Conventional cell-line
derived
NB Rare Khanna et al., 2002
Orthotopic PDX NB Multiple incl.
BM
Braekeveldt et al., 2015
GEMMs
TH-MYCN NB No Weiss et al., 1997
ALKF1174L/MYCN NB No Berry et al., 2012
TH-MYCN/Caspase-8-deleted NB BM Teitz et al., 2013
Lin28b overexpression NB Not reported Molenaar et al., 2012
NF1+/− Pheo Not reported Jacks et al., 1994
Ink4a Arf−/− Pheo Lungs You et al., 2002
PSA-Cre;Pten-loxP/loxP Pheo Lungs Korpershoek et al., 2009
Met918Thr Pheo No Smith-Hicks et al., 2000
c-mos Pheo Not reported Schulz et al., 1992
Germline
Cdkn1b−/− Pheo/PGL Not reported Fritz et al., 2002
Pellegata et al., 2006(2012)). GEMMs have contributed to our understanding of tumor initi-
ation and growth; however, GEMM tumors are by deﬁnition of murine
origin and the models may not necessarily accurately recapitulate the
biological and clinical features of human disease. GEMMs carrying
SDHx mutations have been created, but neither SdhD+/− nor SdhB+/−
mice develop pheochromocytomas or paragangliomas (Piruat et al.,
2004; Bayley et al., 2009). This subject is further reviewed in (Maher
et al., 2011).
Many conventional human neuroblastoma cell lines exist that have
contributed to progress in understanding this disease. Similarly, the
rat PC-12 pheochromocytoma cell line (Greene & Tischler, 1976) and
the mouse MPC pheochromocytoma cell line (Powers et al., 2000)
have been widely used. However, the degree to which conventional
cancer cell lines resemble patient disease has been questioned due to
the tumor cell differentiation and aberrant genetic deviations that
arise following long-term culture in serum-containing media (Lee
et al., 2006). There is thus a need to develop relevant mouse models
with disease-speciﬁc genotypes to target HIF-2 and the pseudohypoxic
phenotype.
Recently established neuroblastoma patient-derived orthotopic xe-
nografts (PDXs), in which surgical resection specimens from patients
are implanted to the para-adrenal space of immunodeﬁcient mice, re-
tain the geno- and phenotypes of patient tumors (Braekeveldt et al.,
2015, 2016). NeuroblastomaPDXs also exhibit inﬁltrative tumor growth
and spontaneous metastatic spread to clinically relevant locations
including the bone marrow. Furthermore, PDX-derived human neuro-
blastoma cells cultured under serum-free stem cell-promoting condi-
tions also retain the genotype and tumorigenic and metastatic
capacity in vivo (Braekeveldt et al., 2015). These cells can be used for
drug testing (Mohlin et al., 2015). A limitation of this model system is
that the mice lack a fully functional immune system and efforts are
therefore beingmade to reconstitute the human immune system in im-
munodeﬁcient mice (Shultz et al., 2014). Nevertheless, neuroblastoma
PDXs in vivo and in vitro will facilitate the identiﬁcation of drugs
targeting hypoxic tumor cells and the pseudohypoxic phenotype in ag-
gressive neuroblastoma. Although these drugs are likely to also be effec-
tive in Cluster 1 pheochromocytomas and paragangliomas, establishing
PDXs and human cell lines from metastatic pheochromocytoma/
paraganglioma would nevertheless be highly desirable.
6. Summary and future perspectives
Tumor hypoxia and its main mediators the HIFs regulate many im-
portant biological hallmarks of cancer ranging from genetic instability
and tumor cell differentiation to metabolic reprogramming and tumor
vascularization. Experimental and clinical data from various tumor
types suggest that HIFs also regulate metastasis and treatment resis-
tance, which account for the majority of cancer-related deaths. Thus,
HIF inhibitors are likely to targetmultiple important carcinogenetic pro-
cesses. Intriguingly, HIF-1 and HIF-2 often have opposing effects on
tumor growth, for instance on crucial cell cycle and apoptotic regulators
like c-MYCandp53. Consequently, speciﬁcHIF-1 orHIF-2 inhibition, de-
pending on the tumor type, is likely to be required for successful clinical
exploitation of HIF action.
Precision-based targeting of speciﬁc growth factors/receptors and/
or pathways is currently being tested in numerous preclinical and clin-
ical trials and some personalized therapies, such as trastuzumab in
breast cancer, are now standard care. Although the targeted approach
has been effective in some tumor types, most if not all of the cancers
treated with targeted drugs eventually become resistant. In addition,
intratumoral heterogeneity and clonal evolution, which are common
in solid tumors, are also likely to contribute to resistance to some
targeted therapies. In contrast, targeting the hypoxic phenotype repre-
sents amore general approach to eradicatemalignant cells. Importantly,
dysregulated HIF-2 is common in various tumor types regardless of
their genetic and molecular diversity, and HIF-2 inhibition could
164 C. Wigerup et al. / Pharmacology & Therapeutics 164 (2016) 152–169potentially overcome the resistance associated with growth factor re-
ceptor inhibition (Franovic et al., 2009). In particular, glioblastoma,
ccRCC, and neuroblastoma represent tumor types that might be
particularly vulnerable to HIF-2 inhibition. Pheochromocytomas and
paragangliomas are also interesting tumor types from the perspective
of HIF-2 inhibition due to their HIF2Amutations and mutations in VHL
and SDH causing a pseudohypoxic phenotype. To optimize their effects,
HIF inhibitors should be combined with conventional chemotherapy
and/or IR. Recent progress in clinical immunotherapy and discoveries
into how HIFs regulate the tumor immune response suggest that
combined immunotherapy and HIF inhibition is likely to be a powerful
therapeutic approach.
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